TL;DR
This study investigated the safety and effectiveness of apixaban in patients with end-stage kidney disease (ESKD) on dialysis. It found that while apixaban was effective in preventing VTE and stroke, the risk of bleeding was significant, with lower Body Mass Index (BMI) being a key independent risk factor.
What Problem Does This Paper Address?
Patients with end-stage kidney disease (ESKD) who require dialysis are at a higher risk for both blood clots (like VTE and stroke) and bleeding complications. Direct oral anticoagulants (DOACs), such as apixaban, are increasingly used for stroke prevention in non-valvular atrial fibrillation (NVAF) and for VTE treatment. However, the safety and effectiveness of apixaban in the ESKD population on dialysis are not fully established. This is particularly challenging because these patients often have co-existing conditions that can affect drug metabolism and increase bleeding risk. The study aims to fill this knowledge gap by evaluating apixaban's outcomes in this specific, vulnerable patient group.
Methods
This study employed a retrospective observational design. Researchers analyzed data from adult patients with ESKD undergoing intermittent hemodialysis who were prescribed apixaban. Data was collected from an outpatient pharmacy between May 2015 and March 2022. The study collected demographic information, reasons for apixaban prescription, dose appropriateness, use of other antiplatelet medications, and co-existing medical conditions. Crucially, they also tracked bleeding events and thromboembolic events (like VTE and stroke). Statistical analysis included descriptive statistics, Mann-Whitney U tests for comparisons, and multivariate logistic regression to identify independent risk factors for bleeding.
Datasets
The study utilized data from patients treated at a quaternary care hospital's outpatient pharmacy. No new datasets were introduced, and no external benchmarks were used for comparison beyond existing literature.
Key Insights and Ideas
- BMI as a Bleeding Predictor: The most striking finding is that lower BMI, not just weight, emerged as a significant independent risk factor for bleeding in this ESKD dialysis population. This suggests that body composition, rather than just overall mass, plays a critical role in bleeding risk with apixaban.
- Apixaban's Dual Role: Apixaban demonstrated effectiveness in preventing VTE and stroke, indicating its therapeutic utility in this high-risk group.
- Bleeding Risk is Real: Despite its effectiveness, the study highlights that the risk of bleeding, both major and minor, is substantial in ESKD patients on dialysis treated with apixaban.
- Dosing Nuances: While appropriate dosing was observed in a majority of patients, the study found that daily dose and weight were not significant predictors of bleeding events, further emphasizing the unique role of BMI.
Key Results
- Patient Cohort: 66 patients with ESKD on dialysis were included.
- Demographics: Median age was 71 years, and median BMI was 28.2 kg/m².
- Adherence and Dosing: High medication adherence (84.8%) and appropriate apixaban dosing (62.1%) were noted.
- Bleeding Events: Major bleeding occurred in 15.2% of patients, and minor bleeding in 36.4%.
- Thromboembolic Events: VTE and stroke events occurred in 4.5% of cases.
- Mortality: The all-cause mortality rate was a significant 34.8%.
- BMI and Bleeding: Multivariate analysis identified BMI as the main independent risk factor for bleeding (OR = 0.9, 95% CI: 0.8–0.99; p = 0.023), indicating that lower BMI is associated with a higher bleeding risk.
- Other Factors: Age and apixaban daily dose were not significant predictors of bleeding.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: This design can introduce bias and confounding factors.
- Small Sample Size: The study included only 66 patients, which limits the generalizability of the findings.
- Lack of Comparative Arm: The study did not include a direct comparison group (e.g., warfarin-treated patients), making it difficult to definitively compare apixaban's outcomes against other anticoagulants.
The authors strongly recommend a larger, prospective study to confirm these findings. They also suggest that future research should explore the role of DOACs in mitigating arteriovenous fistula thrombosis, a critical issue for hemodialysis patients. Additionally, they note the importance of considering risk assessment scores like HAS-BLED, though its utility in hemodialysis patients requires further elucidation.
Summary updated